Plavix Could Face Rival Prasugrel In Second Half
This article was originally published in PharmAsia News
Executive Summary
Lilly and Daiichi Sankyo will launch the antiplatelet drug prasugrel immediately after it is approved, supported by an extensive sales force that includes representatives from both companies, Lilly's head of cardiovascular research, J. Anthony Ware, told "The Pink Sheet" DAILY
You may also be interested in...
Lilly’s Prasugrel Superior To Bristol’s Plavix In Reducing CV Events In Pivotal TRITON Trial
Efficacy tempered by an increase in non-CABG bleeding compared to clopidogrel.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).